316 related articles for article (PubMed ID: 16643518)
1. In-vivo impact of the MexXY efflux system on aminoglycoside efficacy in an experimental model of Pseudomonas aeruginosa pneumonia treated with tobramycin.
Martha B; Croisier D; Durand D; Hocquet D; Plesiat P; Piroth L; Portier H; Chavanet P
Clin Microbiol Infect; 2006 May; 12(5):426-32. PubMed ID: 16643518
[TBL] [Abstract][Full Text] [Related]
2. Role of the MexXY multidrug efflux pump in moderate aminoglycoside resistance in Pseudomonas aeruginosa isolates from Pseudomonas mastitis.
Chuanchuen R; Wannaprasat W; Ajariyakhajorn K; Schweizer HP
Microbiol Immunol; 2008 Aug; 52(8):392-8. PubMed ID: 18667038
[TBL] [Abstract][Full Text] [Related]
3. Expression of the MexXY efflux pump in amikacin-resistant isolates of Pseudomonas aeruginosa.
Islam S; Jalal S; Wretlind B
Clin Microbiol Infect; 2004 Oct; 10(10):877-83. PubMed ID: 15373880
[TBL] [Abstract][Full Text] [Related]
4. In vivo efficacy of humanised intermittent versus continuous ceftazidime in combination with tobramycin in an experimental model of pseudomonal pneumonia.
Croisier D; Martha B; Piroth L; Chavanet P
Int J Antimicrob Agents; 2008 Dec; 32(6):494-8. PubMed ID: 18804348
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and potential for resistance selection of antipseudomonal treatments in a mouse model of lung infection by hypermutable Pseudomonas aeruginosa.
Maciá MD; Borrell N; Segura M; Gómez C; Pérez JL; Oliver A
Antimicrob Agents Chemother; 2006 Mar; 50(3):975-83. PubMed ID: 16495260
[TBL] [Abstract][Full Text] [Related]
6. Functional characterization of MexXY and OpmG in aminoglycoside efflux in Pseudomonas aeruginosa.
Chuanchuen R; Wannaprasat W; Schweizer HP
Southeast Asian J Trop Med Public Health; 2008 Jan; 39(1):115-22. PubMed ID: 18567450
[TBL] [Abstract][Full Text] [Related]
7. Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development?
Burkhardt O; Lehmann C; Madabushi R; Kumar V; Derendorf H; Welte T
J Antimicrob Chemother; 2006 Oct; 58(4):822-9. PubMed ID: 16885180
[TBL] [Abstract][Full Text] [Related]
8. Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents.
Plasencia V; Borrell N; Maciá MD; Moya B; Pérez JL; Oliver A
Antimicrob Agents Chemother; 2007 Jul; 51(7):2574-81. PubMed ID: 17470655
[TBL] [Abstract][Full Text] [Related]
9. Comparative in vivo efficacy of meropenem, imipenem, and cefepime against Pseudomonas aeruginosa expressing MexA-MexB-OprM efflux pumps.
Ong CT; Tessier PR; Li C; Nightingale CH; Nicolau DP
Diagn Microbiol Infect Dis; 2007 Feb; 57(2):153-61. PubMed ID: 16930925
[TBL] [Abstract][Full Text] [Related]
10. [Combined application of ciprofloxacin and tobramycin on mutant selective windows of ciprofloxacin against Pseudomonas aeruginosa].
Liu MT; Sheng MY; Zhang Y; Li Y
Zhonghua Yi Xue Za Zhi; 2011 May; 91(20):1427-31. PubMed ID: 21756818
[TBL] [Abstract][Full Text] [Related]
11. MexZ-mediated regulation of mexXY multidrug efflux pump expression in Pseudomonas aeruginosa by binding on the mexZ-mexX intergenic DNA.
Matsuo Y; Eda S; Gotoh N; Yoshihara E; Nakae T
FEMS Microbiol Lett; 2004 Sep; 238(1):23-8. PubMed ID: 15336398
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamics of tobramycin in patients with cystic fibrosis.
Mouton JW; Jacobs N; Tiddens H; Horrevorts AM
Diagn Microbiol Infect Dis; 2005 Jun; 52(2):123-7. PubMed ID: 15964500
[TBL] [Abstract][Full Text] [Related]
13. Aminoglycoside resistance in
Thacharodi A; Lamont IL
J Med Microbiol; 2022 Jun; 71(6):. PubMed ID: 35708991
[No Abstract] [Full Text] [Related]
14. Induction of the MexXY efflux pump in Pseudomonas aeruginosa is dependent on drug-ribosome interaction.
Jeannot K; Sobel ML; El Garch F; Poole K; Plésiat P
J Bacteriol; 2005 Aug; 187(15):5341-6. PubMed ID: 16030228
[TBL] [Abstract][Full Text] [Related]
15. Involvement of the MexXY-OprM efflux system in emergence of cefepime resistance in clinical strains of Pseudomonas aeruginosa.
Hocquet D; Nordmann P; El Garch F; Cabanne L; Plésiat P
Antimicrob Agents Chemother; 2006 Apr; 50(4):1347-51. PubMed ID: 16569851
[TBL] [Abstract][Full Text] [Related]
16. MexXY-OprM efflux pump is required for antagonism of aminoglycosides by divalent cations in Pseudomonas aeruginosa.
Mao W; Warren MS; Lee A; Mistry A; Lomovskaya O
Antimicrob Agents Chemother; 2001 Jul; 45(7):2001-7. PubMed ID: 11408215
[TBL] [Abstract][Full Text] [Related]
17. Relationship between antibiotic use and incidence of MexXY-OprM overproducers among clinical isolates of Pseudomonas aeruginosa.
Hocquet D; Muller A; Blanc K; Plésiat P; Talon D; Monnet DL; Bertrand X
Antimicrob Agents Chemother; 2008 Mar; 52(3):1173-5. PubMed ID: 18180356
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of a new tobramycin (0.3%) and dexamethasone (0.05%) formulation in the treatment of experimental Pseudomonas keratitis.
McCormick C; Caballero A; Tang A; Balzli C; Song J; O'Callaghan R
Curr Med Res Opin; 2008 Jun; 24(6):1569-75. PubMed ID: 18423106
[TBL] [Abstract][Full Text] [Related]
19. Comparison of in vivo intrinsic activity of cefepime and imipenem in a Pseudomonas aeruginosa rabbit endocarditis model: effect of combination with tobramycin simulating human serum pharmacokinetics.
Navas D; Caillon J; Gras-Le Guen C; Jacqueline C; Kergueris MF; Bugnon D; Potel G
J Antimicrob Chemother; 2004 Oct; 54(4):767-71. PubMed ID: 15317741
[TBL] [Abstract][Full Text] [Related]
20. Augmented effect of early antibiotic treatment in mice with experimental lung infections due to sequentially adapted mucoid strains of Pseudomonas aeruginosa.
van Gennip M; Moser C; Christensen LD; Bjarnsholt T; Calum H; Jensen PØ; Christophersen L; Hougen HP; Ciofu O; Molin S; Givskov M; Høiby N
J Antimicrob Chemother; 2009 Dec; 64(6):1241-50. PubMed ID: 19815632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
